A Phase 2 interventional study of Docetaxel + Oxaliplatin and Docetaxel + Oxaliplatin + 5-FU in Stomach Neoplasms, sponsored by Sanofi. Completed at 12 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-01-07.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies testing docetaxel in Stomach Neoplasms — 9 open to participants now, 13 under way, 5 of them phase 3. Docetaxel · Stomach Neoplasms.
Among the 103 studies testing docetaxel in Stomach Neoplasms, this one is the 8th largest by enrollment of the 99 interventional ones that give a count, is one of 11 that started in 2006, is one of 71 in phase 2, and was the 19th registered.
3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.
Browse Stomach Neoplasms studies →9 of the 103 studies testing docetaxel in Stomach Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Canada, China and 8 more countries
Ages 18+
Asan Medical Center · Sites in Korea, Republic of
Ages 19+
Ukrainian Society of Clinical Oncology · Sites in Lithuania, Ukraine
Ages 18–80
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Sites in China
Ages 18–75
Asan Medical Center · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →
Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
103 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 84 · Phase 3 13
First in 1997; this study’s year is marked. 11 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 275 is above the median of 66 across 2,502 interventional studies indexed under Stomach Neoplasms.
Median enrollment 50 across the 99 interventional studies. Of the 68 that completed or were terminated, 21 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 103 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
15 studies in Stomach Neoplasms by Sanofi: 1 open now, 1 under way, none of them phase 3. Of 14 finished, 4 (29%) have results posted.
Among the 15 studies in Stomach Neoplasms by Sanofi, this one is the 4th largest by enrollment, is one of 3 that started in 2006, is one of 7 in phase 2, and was the 4th registered.
Sanofi’s Stomach Neoplasms studies by the year they started, since 1998.
4 of the studies testing docetaxel in Stomach Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06028737Phase 3Ukrainian Society of Clinical OncologyTotal Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer | 2027-04-25 |
| NCT07257575Guangdong Provincial People's HospitalA Randomized Controlled Study of Serplulimab Combined With Chemotherapy for Locally Advanced Gastric Adenocarcinoma | 2027-01-31 |
| NCT05184803Asan Medical CenterA Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer | 2027-06-30 |
| NCT07069712AstraZenecaA Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma | 2027-11-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 103 studies testing docetaxel in Stomach Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 15 in Stomach Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This phase II study addressed the use of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease. Prior to this study a pilot phase I (part I) determined the optimal dose by assessing the safety and tolerability of 2 dose levels in each arm. The optimal dose was administered in the Part II study. Participants who received the optimal dose in each treatment arm in Part I were included in the Part II analysis population.
Primary objective:
Secondary objectives:
The purpose of this study (Part II) was to evaluate the time to progression in the 3 arms at an optimal dose level of docetaxel and oxaliplatin defined during a prior pilot (Part I) phase study. The estimated duration of treatment was to be 6 months. Treatment was to be administered up to progression, unacceptable toxicities, or withdrawal of consent. The reason and date of removal of all participants was documented on the case report form.
Participants who ended treatment but had not yet progressed (e.g. unacceptable toxicities or withdrawal of consent) were be followed every 8 weeks with a complete tumor assessment until documented progression or further anti-tumor therapy. Then, they would be followed every 3 months after progression for survival status; date of death or progression were reported. Participants who ended treatment for progression, were to be followed every 3 months until death. Date of death was reported. The planned duration of the study was 30 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Docetaxel (Taxotere) in combination with Oxaliplatin (Eloxatin). Each chemotherapy cycle was repeated every 21 days. Participants received either the optimal or non-optimal dose for Taxotere and Eloxatin. Participants who received the optimal dose for Taxotere and Eloxatin were analyzed in this study.
Drug: Docetaxel + Oxaliplatin
Docetaxel (Taxotere) in combination with Oxaliplatin (Eloxatin) and 5-FU (5-Fluorouracil). Each chemotherapy cycle was repeated every 14 days. Participants received either the optimal or non-optimal dose for Taxotere, Eloxatin and 5-FU. Participants who received the optimal dose for Taxotere, Eloxatin and 5-FU were analyzed in this study.
Drug: Docetaxel + Oxaliplatin + 5-FU
Docetaxel (Taxotere) in combination with Oxaliplatin (Eloxatin) and capecitabine (Xeloda). Each chemotherapy cycle was repeated every 21 days. Participants received either the optimal or non-optimal dose for Taxotere, Eloxatin and Xeloda. Participants who received the optimal dose for Taxotere, Eloxatin and Xeloda were analyzed in this study.
Drug: Docetaxel + Oxaliplatin + Capecitabine
Drug pages: Docetaxel · Oxaliplatin
Dose level 1 (non-optimal dose): Docetaxel 75 mg/m² as an 1-hour intravenous (IV) infusion on day 1 followed by Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1 Dose level 2 (optimal dose): Docetaxel 75 mg/m² as an 1-hour IV infusion on day 1 followed by Oxaliplatin 130 mg/m² as a two to six-hour IV infusion on day 1
Drug pages: Docetaxel · Oxaliplatin · Fluorouracil
Dose level 1 (non-optimal dose): Docetaxel 40 mg/m² as a 1-hour intravenous (IV) infusion day 1; Oxaliplatin 85 mg/m² simultaneously with folinic acid 400 mg/m² as a 2-hour IV infusion, followed by 5-FU 2400 mg/m2 as a 46-hour continuous infusion day 1. Dose level 2 (optimal dose): Docetaxel 50 mg/m² as a 1-hour IV infusion day 1; Oxaliplatin 85 mg/m² simultaneously with folinic acid 400 mg/m² as a 2-hour IV infusion, followed by 5-FU 2400 mg/m² as a 46-hour continuous infusion day 1.
Drug pages: Docetaxel · Oxaliplatin · Capecitabine
Dose level 1 (optimal dose): Docetaxel 50 mg/m² as a 1-hour intravenous (IV) infusion on day 1, Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1, Capecitabine 625 mg/m2 two times a day continuously. Dose level 2 (non-optimal dose): Docetaxel 65 mg/m² as a 1-hour IV infusion on day 1, Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1, Capecitabine 625 mg/m² two times a day continuously.
Time to Progression
The number of months measured from the day of randomization to the first tumor progression according to World Health Organization (WHO) criteria evaluation of cancer response, or death from any cause. WHO Criteria for Progressive Disease: ≥ 25% increase in the size of at least one bidimensionally or unidimensionally measurable lesion.
Time frame: every 8 weeks up to a maximum of 36 months
Best Overall Response Rate (ORR)
Percentage of partial and complete responses, according to WHO criteria: Complete Response: Disappearance of all known disease, determined by 2 observations not less than 4 weeks apart. Partial Response: Decrease by at least 50% of the diameters of all measurable lesions, determined by 2 observations not less than 4 weeks apart.
Time frame: every 8 weeks up to a maximum of 36 months
Overall Survival (OS)
The number of months measured from the date of randomization to the date of death due to any cause.
Time frame: up to a maximum of 36 months
A total 275 participants from 12 countries were randomized in the part I/II study. 64 participants were enrolled in Part I. 211 new participants were enrolled specifically for Part II.
| Milestone | (TE) Taxotere and Eloxatin | (TEF) Taxotere, Eloxatin and 5-fluorouracil | (TEX) Taxotere, Eloxatin and Xeloda |
|---|---|---|---|
| Started | 79 | 89 | 86 |
| Administered non-optimal dose (part i) | 10 | 11 | 0 |
| Administered optimal dose (parts i & ii) | 78 | 88 | 82 |
| Full analysis population (fap) | 78 | 88 | 82 |
| Completed | 0 | 0 | 0 |
| Not completed | 79 | 89 | 86 |
| Withdrew: Adverse event | 21 | 23 | 15 |
| Withdrew: Protocol violation | 2 | 5 | 1 |
| Withdrew: Death | 0 | 1 | 2 |
| Withdrew: Progressive disease | 37 | 28 | 38 |
| Withdrew: Withdrew consent | 1 | 1 | 2 |
| Withdrew: Withdrawal by subject | 11 | 20 | 12 |
| Withdrew: Surgery | 1 | 1 | 4 |
| Withdrew: Patient did not receive study medication | 1 | 1 | 4 |
| Withdrew: Clinically progressive disease | 0 | 1 | 0 |
| Withdrew: Good prognosis | 0 | 1 | 0 |
| Withdrew: Investigator/clinical decision | 5 | 6 | 6 |
| Withdrew: Discontinued at end of study | 0 | 1 | 2 |
The number of months measured from the day of randomization to the first tumor progression according to World Health Organization (WHO) criteria evaluation of cancer response, or death from any cause. WHO Criteria for Progressive Disease: ≥ 25% increase in the size of at least one bidimensionally or unidimensionally measurable lesion.
| Months | (TE) Taxotere and Eloxatin | (TEF) Taxotere, Eloxatin and 5-fluorouracil | (TEX) Taxotere, Eloxatin and Xeloda |
|---|---|---|---|
| Time to Progression | 4.50 (3.68 to 5.32) | 7.66 (6.97 to 9.40) | 5.55 (4.30 to 6.37) |
Percentage of partial and complete responses, according to WHO criteria: Complete Response: Disappearance of all known disease, determined by 2 observations not less than 4 weeks apart. Partial Response: Decrease by at least 50% of the diameters of all measurable lesions, determined by 2 observations not less than 4 weeks apart.
| percentage of participants | (TE) Taxotere and Eloxatin | (TEF) Taxotere, Eloxatin and 5-fluorouracil | (TEX) Taxotere, Eloxatin and Xeloda |
|---|---|---|---|
| Best Overall Response Rate (ORR) | 23.1 (14.3 to 34.0) | 46.6 (35.9 to 57.5) | 25.6 (16.6 to 36.4) |
The number of months measured from the date of randomization to the date of death due to any cause.
| months | (TE) Taxotere and Eloxatin | (TEF) Taxotere, Eloxatin and 5-fluorouracil | (TEX) Taxotere, Eloxatin and Xeloda |
|---|---|---|---|
| Overall Survival (OS) | 8.97 (7.79 to 10.87) | 14.59 (11.70 to 21.78) | 11.30 (8.08 to 14.03) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| (TE) Taxotere and Eloxatin | — | 35/78 (44.9%) | 75/78 (96.2%) |
| (TEF) Taxotere, Eloxatin and 5-fluorouracil | — | 24/88 (27.3%) | 87/88 (98.9%) |
| (TEX) Taxotere, Eloxatin and Xeloda | — | 36/82 (43.9%) | 77/82 (93.9%) |
| Event | (TE) Taxotere and Eloxatin | (TEF) Taxotere, Eloxatin and 5-fluorouracil | (TEX) Taxotere, Eloxatin and Xeloda |
|---|---|---|---|
| diarrheaGastrointestinal disorders | 7/78 | 3/88 | 2/82 |
| febrile neutropeniaBlood and lymphatic system disorders | 7/78 | 2/88 | 5/82 |
| pulmonary embolismRespiratory, thoracic and mediastinal disorders | 4/78 | 1/88 | 2/82 |
| general physical health deteriorationGeneral disorders | 3/78 | 1/88 | 1/82 |
| vomitingGastrointestinal disorders | 2/78 | 3/88 | 3/82 |
| decreased appetiteMetabolism and nutrition disorders | 0/78 | 0/88 | 3/82 |
| anemiaBlood and lymphatic system disorders | 2/78 | 0/88 | 1/82 |
| pyrexiaGeneral disorders | 2/78 | 1/88 | 0/82 |
| gastroenteritisInfections and infestations | 2/78 | 0/88 | 0/82 |
| dehydrationMetabolism and nutrition disorders | 2/78 | 0/88 | 1/82 |
| Event | (TE) Taxotere and Eloxatin | (TEF) Taxotere, Eloxatin and 5-fluorouracil | (TEX) Taxotere, Eloxatin and Xeloda |
|---|---|---|---|
| diarrhoeaGastrointestinal disorders | 48/78 | 59/88 | 53/82 |
| nauseaGastrointestinal disorders | 45/78 | 52/88 | 43/82 |
| alopeciaSkin and subcutaneous tissue disorders | 25/78 | 47/88 | 36/82 |
| fatigueGeneral disorders | 35/78 | 45/88 | 39/82 |
| vomitingGastrointestinal disorders | 36/78 | 30/88 | 30/82 |
| decreased appetiteMetabolism and nutrition disorders | 32/78 | 36/88 | 37/82 |
| stomatitisGastrointestinal disorders | 19/78 | 39/88 | 21/82 |
| peripheral sensory neuropathyNervous system disorders | 27/78 | 33/88 | 25/82 |
| abdominal painGastrointestinal disorders | 24/78 | 19/88 | 16/82 |
| astheniaGeneral disorders | 21/78 | 22/88 | 16/82 |
| Age Continuous(years) | (TE) Taxotere and Eloxatin | (TEF) Taxotere, Eloxatin and 5-fluorouracil | (TEX) Taxotere, Eloxatin and Xeloda | Total |
|---|---|---|---|---|
| Mean | 59.2 ± 11.4 | 57.9 ± 11.1 | 59.0 ± 11.0 | 58.7 ± 11.1 |
| Sex: Female, Male(Participants) | (TE) Taxotere and Eloxatin | (TEF) Taxotere, Eloxatin and 5-fluorouracil | (TEX) Taxotere, Eloxatin and Xeloda | Total |
|---|---|---|---|---|
| Female | 28 | 28 | 22 | 78 |
| Male | 51 | 61 | 64 | 176 |
| Race/Ethnicity, Customized(participants) | (TE) Taxotere and Eloxatin | (TEF) Taxotere, Eloxatin and 5-fluorouracil | (TEX) Taxotere, Eloxatin and Xeloda | Total |
|---|---|---|---|---|
| Asian/Oriental | 0 | 1 | 0 | 1 |
| Black | 1 | 0 | 0 | 1 |
| White | 77 | 87 | 84 | 248 |
| Unknown or Not Reported | 1 | 1 | 2 | 4 |
| Karnofsky Performance Status (KPS)(participants) | (TE) Taxotere and Eloxatin | (TEF) Taxotere, Eloxatin and 5-fluorouracil | (TEX) Taxotere, Eloxatin and Xeloda | Total |
|---|---|---|---|---|
| 100% Normal, no complaints: no evidence of disease | 19 | 28 | 19 | 66 |
| 90% Able to carry on normal activity; minor signs | 26 | 35 | 31 | 92 |
| 80% Normal activity with effort, some signs | 31 | 24 | 33 | 88 |
| 70% Cares for self but unable to work | 1 | 2 | 3 | 6 |
| <70% Requires assistance | 1 | 0 | 0 | 1 |
| Missing | 1 | 0 | 0 | 1 |
| Weight loss during last 3 months(participants) | (TE) Taxotere and Eloxatin | (TEF) Taxotere, Eloxatin and 5-fluorouracil | (TEX) Taxotere, Eloxatin and Xeloda | Total |
|---|---|---|---|---|
| less than or equal to 5% | 39 | 47 | 44 | 130 |
| greater than 5% | 39 | 42 | 41 | 122 |
| Missing | 1 | 0 | 1 | 2 |
The record gives a start of Sep 2006, a primary completion of Apr 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2011, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Docetaxel · Oxaliplatin · Fluorouracil · Capecitabine